Related Experiment Videos
Acinetobacter baumannii bloodstream infection: clinical features and antimicrobial susceptibilities of isolates
1Department of Family Medicine, China Medical College Hospital, Taichung, Taiwan, Republic of China.
Abstract:
The number of nosocomial infections caused by Acinetobacter baumannii has increased in recent years. The purposes of this study are to discover the risk factors of transmission to prevent the nosocomial infection of A. baumannii. We retrospectively studied 36 patients with A. baumannii bacteremia at China Medical College Hospital from January 1996 to December 1997. There were 23 males and 13 females. All bacteremia were acquired nosocomially. Malignancy (n = 8) and intracranial hemorrhage (n = 6) were the most common underlying diseases. Only one patient on arterial line disclosed intraarterial catheter-related A. baumannii bacteremia and 3 patients had evidence of A. baumannii pneumonia. Twenty-one patients (58%) had central venous catheters in place at the onset of bacteremia, but none was proven to be catheter-related infection. There were 32 patients (89%) with unknown portal of entry. Multivariate logistic regression analysis revealed that potential risk factors related to A. baumannii bacteremia were prior antimicrobial therapy (P < 0.05). The most common clinical features of A. baumannii bacteremia were, in descending order, fever, leukocytosis, thrombocytopenia and hypotension. Eleven patients (30.6%) died directly from A. baumannii bacteremia. All isolates were resistant to ampicillin, cephalothin, cefonicid and moxalactam. The most alarming evidence was that 19% of isolates showed resistance to imipenem. Our findings emphasized that A. baumannii bacteremia had the following characteristics: usually acquired nosocomially, unknown portal of entry, and high multiresistance, especially the increasing resistance rate to imipenem. Imipenem must be reserved as a last-line agent to treat A. baumannii infections, so we want to suggest that the treatment of choice for A. baumannii is gentamicin, amikacin or ceftazidime.
Insights
Prior antimicrobial therapy is a key risk factor for Acinetobacter baumannii nosocomial infections. This study highlights the high multidrug resistance of A. baumannii, emphasizing the need for judicious antibiotic use.
Area of Science:
- Infectious Diseases
- Clinical Microbiology
- Hospital Epidemiology
Background:
- Nosocomial infections caused by Acinetobacter baumannii are a growing concern.
- Understanding transmission risk factors is crucial for prevention.
Purpose of the Study:
- To identify risk factors for Acinetobacter baumannii transmission.
- To inform strategies for preventing nosocomial A. baumannii infections.
Main Methods:
- Retrospective study of 36 patients with A. baumannii bacteremia.
- Analysis of patient data including underlying diseases, procedures, and outcomes.
- Multivariate logistic regression to identify risk factors.
Main Results:
- Prior antimicrobial therapy was a significant risk factor (P < 0.05).
- Common features included fever, leukocytosis, thrombocytopenia, and hypotension.
- High multidrug resistance observed, with 19% of isolates resistant to imipenem.
- Mortality rate directly from A. baumannii bacteremia was 30.6%.
Conclusions:
- Acinetobacter baumannii bacteremia is often nosocomially acquired with an unknown portal of entry.
- High multidrug resistance, particularly to imipenem, is a major challenge.
- Gentamicin, amikacin, or ceftazidime are suggested as preferred treatments.